Techbio SimBioSys and the Mayo Clinic have entered into a strategic collaboration to develop novel digital precision medicine solutions for breast cancer.
The aim of the collaboration is to develop cloud-based clinical software tools that will support the end-to-end decision-making process for early-stage breast cancer patients, including drug selection and risk stratification.
Mayo Clinic physicians Judy Boughey, Division Chair of Breast and Melanoma Surgical Oncology and Chair of the Mayo Clinic Comprehensive Cancer Center Breast Cancer Disease Group, and Matthew Goetz, Enterprise Deputy Director of Translational Research and Director of Mayo Clinic Breast Cancer SPORE, are part of the SimBioSys clinical advisory team to support the ongoing development of the clinical software tools.
As part of the collaboration, SimBioSys is analysing data from patients who participated in the Mayo Clinic-led BEAUTY clinical trial. The company will perform simulations using previously acquired data and, while validating the predictive accuracy of the platform, will also perform in-silico scenario analysis guided by the Mayo Clinic team.
“In the crowded world of genomics, new approaches have many barriers to becoming a new standard of care,” said Tushar Pandey, Co-founder and CEO of SimBioSys. “We are delighted to collaborate with Mayo Clinic as we bring our innovative technology to patients.”
Mayo Clinic has been designated a Comprehensive Cancer Center by the National Cancer Institute and is one of only 45 NCI-designated comprehensive centres in the United States.